Please login to the form below

Not currently logged in
Email:
Password:

Innovative Medicines Initiative appoints executive director

Pierre Meulien joins from Genome Canada 

edit-Innovative-Medicines-Initiative-pierre-meulienInnovative Medicines Initiative (IMI) has named Pierre Meulien as executive director, effective from September.

Meulien is currently president and CEO of Genome Canada, a not-for-profit organisation that aims to find new uses for genomics. At the organisation, he successfully secured funding from the Canadian government and leveraged further funding through partnerships.

Commenting on his appointment, Meulien said: “I am delighted to have been selected to lead the second phase of the Innovative Medicines Initiative. 

“This unique joint venture will deliver health innovations to millions of European citizens and solidify an important industry based in Europe that will be a source of jobs and growth in all of the member states.”

Prior to joining Genome Canada in 2010, Meulien served as CSO for Genome British Columbia, where he promoted the organisation's scientific strategy, and prior to that was founding CEO of the Dublin Molecular Medicine Centre.

Carlos Moedas, European commissioner for research, science and innovation, said: “The excellent results coming out of IMI's projects contribute to improving public health and are stimulating innovation and job creation in Europe. Pierre Meulien's invaluable experience will help IMI deliver on its ambitious objectives.”

22nd June 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics